High-risk del 5q myeloid disease
Proposal for a protocol by Prof. E. Hellström-Lindberg
ELN discussion 2006

• Patients with MDS IPSS Int-2 / High or AML with a karyotype including deletion 5q have an overall poor prognosis due to
  – Short survival, untreated
  – Lower than average CR rate to induction chemotherapy
  – Higher than average relapse rate after allo SCT

• Lenalidomide has shown activity in ”low-risk” MDS with complex karyotype including del5q
High-risk del 5q myeloid disease
Proposal for a protocol
ELN discussion 2006

• Eligible patients (all with a karyotype including del 5q (or those who lack 5q31?))
  1. High-risk MDS and AML not suitable for induction chemotherapy
  2. High-risk MDS and AML, refractory to induction chemotherapy
  3. High-risk MDS and AML, relapsing after induction chemotherapy
  4. Myeloid disease with del 5q relapsing after allo SCT

• Treatment: Lenalidomide according to a dose finding schedule. 8-12 weeks

• Possibility of adding another drug, e.g. hypomethylation in case of no response
High-risk del 5q myeloid disease
Proposal for a protocol
ELN discussion 2006

• Participants
  – ELN WP 5 and 8
  – European Study Groups for MDS / AML

• Since there most likely are competing studies ongoing, the different study groups could chose from the different eligibility groups

• Overall platform, support and trial registry: ELN

• Local management (ethics, MPA, etc) by study group